Fig. 1 · Structure

Documents & Downloads

Madecassic acid

Cat. No. A12086 CAS 18449-41-7
Madecassic acid has anti-inflammatory effects via the suppression of NF-kappaB pathway in LPS-induced RAW 264.7 macrophage cells

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
iNOS  
COX-2  
IL-1β  
IL-6  

Madecassic acid Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Madecassic acid from 3 published references. In vitro models include GST-fused human PPARγ-LBD.

Madecassic acid In Vitro Studies

Madecassic acid was incubated with GST-fused human PPARγ-LBD for 3 h in the dark at room temperature. A competitive TR-FRET assay showed binding to PPARγ with a kinetic inhibition constant (Ki) of 1.61 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Binding to Human PPARγ Ligand-Binding Domain

Cell-based study · GST-fused human PPARγ-LBD [1]

GST-fused human PPARγ-LBD was incubated with Madecassic acid for 3 h in the dark at room temperature. A competitive TR-FRET assay showed binding to PPARγ with a kinetic inhibition constant (Ki) of 1.61 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding of madecassic acid to PPARγ-LBD in a competitive TR-FRET assay.Ki Ki) of 1.61 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
for 3 h in the dark at room temperature
Method
cultured with GST-fused human PPARγ-LBD
Vehicle
dimethyl sulfoxide (DMSO); phosphate-buffered saline
Reported limits
Not stated in the sentences used: dose, control.
Methods and source locations

Compound reported in the paper: Madecassic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Madecassic acid acted as a PPARγ agonist (S59); Materials and methods > Reagents (S70); Materials and methods > PPARγ competitive binding assay (S130); Figure 7 legend (S240)

Binding of madecassic acid to PPARγ-LBD in a competitive TR-FRET assay.: Binding of madecassic acid to PPARγ-LBD in a competitive TR-FRET assay. — Results > Madecassic acid acted as a PPARγ agonist (S59); Figure 7 legend (S240)

Madecassic acid In Vivo Studies

In female mice with DSS-induced colitis, orally administered Madecassic acid decreased the Th17/Treg cell ratio to 0.46 and 0.34 at 12.5, 25 mg/kg, respectively, versus the DSS group. Another study in female mice with DSS-induced colitis reported reduced colonic IL-17 expression following Madecassic acid treatment versus the DSS group. In male mice receiving a high-fat diet, intraperitoneal Madecassic acid restored acetylcholine-induced relaxation in aortic segments compared with HF-C. [1,2,3]

Th17/Treg Cell Ratio in DSS-Induced Colitis

Animal study · Female C57BL/6 mice; DSS-induced colitis; n=5–8 [1]

Female mice with DSS-induced colitis received Madecassic acid orally at 12.5, 25 mg/kg daily for 10 days. Compared with the DSS group, the Th17/Treg cell ratio decreased to 0.46 and 0.34, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ratio of Th17/Treg cellsTh17/Treg ratio 0.46 and 0.34[1]

Conditions shared by the study groups

Route
orally administered
Treatment course
daily for 10 days
Vehicle
0.5% sodium carboxy methyl cellulose (CMC-Na)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Madecassic acid 12.5, 25 mg/kgDSS groupMadecassic acid (12.5, 25 mg/kg) decreased the ratio of Th17/Treg cells to 0.46 and 0.34, respectively.[1]
Madecassic acid 12.5, 25 mg/kg
Model: Female C57BL/6 mice; DSS-induced colitis; n=5–8
Methods and source locations

Compound reported in the paper: Madecassic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S12, S13); Materials and methods > Reagents (S69); Materials and methods > Animals (S89); Materials and methods > Induction and assessment of DSS-induced colitis and drug administration (S92); Materials and methods > Intracellular staining and flow cytometry (S111, S112); Figure 1 legend (S146); Figure 2 legend (S160, S161, S162, S171)

ratio of Th17/Treg cells: ratio of Th17/Treg cells; comparator: DSS group — Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S12, S13)

Madecassic acid 12.5, 25 mg/kg · Results > Madecassic acid restored the Th17/Treg balance in mice with DSS-induced colitis (S13); Materials and methods > Induction and assessment of DSS-induced colitis and drug administration (S92); Figure 2 legend (S162)

Colonic IL-17 Expression in DSS-Induced Colitis

Animal study · female C57BL/6 mice; DSS-induced colitis; six mice per group [2]

In female mice with DSS-induced colitis, Madecassic acid orally gavaged at 25 mg/kg daily for 10 days reduced IL-17 expression in colon tissues versus the DSS group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of IL-17 in colon tissuesReported result reduced the expression of IL-17 in colon tissues[2]

Conditions shared by the study groups

Route
orally gavaged
Treatment course
daily for 10 days
Vehicle
carboxyl methyl cellulose sodium (CMC-Na, 0.5%)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Madecassic acid 25 mg/kgDSS groupreduced the expression of IL-17 in colon tissues[2]
Madecassic acid 25 mg/kg
Model: female C57BL/6 mice; DSS-induced colitis; six mice per group
Methods and source locations

Compound reported in the paper: Madecassic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6); Materials and methods > DSS-induced colitis in mice (S88, S89); Fig. 1 legend (S151, S153); Fig. 7 legend (S167)

expression of IL-17 in colon tissues: expression of IL-17 in colon tissues; comparator: DSS group — Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6)

Madecassic acid 25 mg/kg · Results > γδT17 cells are the main target cells of MA for reducing the expression of IL-17 in the colon of colitis mice (S6); Materials and methods > DSS-induced colitis in mice (S89)

Acetylcholine-Induced Relaxation in Aortic Segments

Animal study · male C57BL/6 J mice; aortic segments from HF mice [3]

In aortic segments from male mice fed a high-fat diet, Madecassic acid administered intraperitoneally at 20 mg/kg daily for 4 weeks restored acetylcholine-induced relaxation compared with HF-C.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Emax AChReported result MA restored Ach-induced relaxation; HF-MA: 86.5 ± 3.6; HF-C: 64.1 ± 4.2; p < 0.001 compared with HF-C[3]

Conditions shared by the study groups

Route
intraperitoneally (i.p)
Treatment course
daily; 4 weeks
Vehicle
saline with 1% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Madecassic acid 20 mg/kgHF-CMA restored Ach-induced relaxation; HF-MA: 86.5 ± 3.6; HF-C: 64.1 ± 4.2; p < 0.001 compared with HF-C[3]
Madecassic acid 20 mg/kg
Model: male C57BL/6 J mice; aortic segments from HF mice
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Madecassic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and dietary treatments (S1, S2, S4, S5); Materials and Methods > Vascular reactivity in isolated aortic arteries cleaned of PVAT (S33, S35); Results > Treatment with EAE or MA improved endothelial function in HF mice (S90, S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)

Emax ACh: Emax ACh; comparator: HF-C — Results > Treatment with EAE or MA improved endothelial function in HF mice (S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)

Madecassic acid 20 mg/kg · Materials and Methods > Animals and dietary treatments (S4, S5); Results > Treatment with EAE or MA improved endothelial function in HF mice (S91); Table 2 legend (S145); Table 2 (T2.h1, T2.r1)

Specifications

Manufacturer Adooq Bioscience
CAS Number 18449-41-7
Formula C30H48O6
Molecular Weight 504.71
SMILES
OC[C@]1(C)[C@@H](O)[C@H](O)C[C@@]2(C)[C@@]1([H])[C@H](O)C[C@]3(C)[C@]2([H])CC=C4[C@@]3(C)CC[C@]5(C(O)=O)[C@@]4([H])[C@@H](C)[C@H](C)CC5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (174.35 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Madecassic acid Research References

  1. [1] Xu X, Wang Y, Wei Z, et al. Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway. Cell Death Dis (2017). PMID: 28358365 DOI: 10.1038/cddis.2017.150 Source material
  2. [2] Yun X, Fang Y, Lv C, et al. Inhibition of the activation of γδT17 cells through PPARγ-PTEN/Akt/GSK3β/NFAT pathway contributes to the anti-colitis effect of madecassic acid. Cell Death Dis (2020). PMID: 32929062 DOI: 10.1038/s41419-020-02969-x Source material
  3. [3] Arancibia-Radich J, González-Blázquez R, Alcalá M, et al. Beneficial effects of murtilla extract and madecassic acid on insulin sensitivity and endothelial function in a model of diet-induced obesity. Sci Rep (2019). PMID: 30679477 DOI: 10.1038/s41598-018-36555-1 Source material

Added to your cart

View Cart Checkout
Loading...